Food and Drug Administration Improvement Act of 2005

Bill: 109-hr-2090
Sponsor: Rep. Hinchey, Maurice D. [D-NY-22]
Introduced: 2005-05-04 in the House
Policy area: Health
Subjects: Administrative fees
Animals
Clinical trials
Commerce
Communication in medicine
Conflict of interests
Consumer education
Consumer protection
Data banks
Department of Health and Human Services
Drug advertising
Drug approvals
Drug industry
Drugs
Economics and Public Finance
Executive reorganization
Federal advisory bodies
Federal-state relations
Fines (Penalties)
Food and Drug Administration (FDA)
Government Operations and Politics
Government and business
Government ethics
Government publicity
Health education
Health information systems
Informed consent (Medical law)
Labeling
Law
Medical ethics
Medical research
Medical supplies
Parties to actions
Physicians
Product safety
Products liability
Science, Technology, Communications
State courts
State laws
Veterinary medicine
Warning labels

Summary:
action_date: 2005-05-04
text: 
Food and Drug Administration Improvement Act of 2005 - Amends the Federal Food, Drug, and Cosmetic Act (FFDCA) to require that all fees collected for the review of applications for human drugs, devices, and animal drugs be deposited in the general fund of the Treasury. Makes available amounts necessary for the Secretary of Health and Human Services to review such applications.
 
Prohibits the Secretary from entering into agreements with persons from whom such fees are collected and terminates any existing agreements.
 
Requires the Secretary to: (1) establish the Center for Postmarket Drug Safety and Effectiveness within the Food and Drug Administration (FDA) to regulate approved drugs; and (2) transfer to the Center all responsibilities for such regulation from the Center for Drug Evaluation and Research and the Center for Biologics Evaluation and Research.
 
Allows the Secretary to require manufacturers of approved drugs to conduct studies of an identified significant safety issue with the drug.
 
Deems a drug to be misbranded if it does not meet the Secretary's requirements, including requirements for labeling and conducting postmarket studies.
 
Requires the Secretary to follow the interpretation that the FDA used in 1999 that the FFDCA and Public Health Service Act establish minimal standards but do not preclude additional state requirements. Requires the Secretary to cease intervening in product liability civil actions to argue another interpretation.
 
Sets forth procedures for advisory committee meetings to ensure that the committee is fairly balanced. Prohibits any exemptions from being granted to advisory committee members from rules prohibiting members from having a personal financial interest in the outcome.
 
Requires doctors to inform patients and obtain consent to prescribe an approved drug for a purpose that has not been approved by the FDA.


Legislative actions:
action_date: 2006-06-21
text: Sponsor introductory remarks on measure. (CR H4358-4359)
action_date: 2005-05-23
text: Referred to the Subcommittee on Health.
action_date: 2005-05-04
text: Referred to the House Committee on Energy and Commerce.
action_date: 2005-05-04
text: Introduced in House
action_date: 2005-05-04
text: Introduced in House